Deltex Medical Group PLC New Monitor Sales in USA and UK (6093X)
February 23 2017 - 2:01AM
UK Regulatory
TIDMDEMG
RNS Number : 6093X
Deltex Medical Group PLC
23 February 2017
23 February 2017
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
New monitor sales in USA and UK
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that
it has received confirmation of monitor orders worth over GBP0.2m
which, as indicated in the trading update announced on 18 January
2017 had moved into 2017 due to the rescheduling of capital
allocations in a small number of hospitals.
The largest value sales contract is from the USA for six
monitors from a seven hospital system in the Company's Great Lakes
sales territory. The customer had originally planned to start
implementation of ODM within its flagship hospital from April 2016
but, following delays in its procurement processes, has now decided
to start implementation simultaneously in two additional
hospitals.
The other major order is for 13 monitors from a consortium of
NHS hospitals in the UK, comprising replacements for nine
previously purchased monitors and four additional units.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"We are encouraged that we have been able to secure capital
funding for our ODM monitors from major customers in both the USA
and UK at a time of restricted capital budgets. The US sales
contract means we can now move forward with supporting
implementation of ODM in one of the most presitigious of the US
platform accounts we announced in 2016."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTEANAAADKXEFF
(END) Dow Jones Newswires
February 23, 2017 02:01 ET (07:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024